A working field guide for medical weight-loss clinic owners, hormone and metabolic health practice CFOs, and growth heads running GLP-1 advertising programmes in the United States. Written against the FDA compounding framework at 21 USC 353a and 353b, the Federal Food, Drug, and Cosmetic Act off-label promotion rules, Meta's Personal Attributes and health-and-wellness policies, TikTok's Community Guidelines and health-content restrictions, and the state medical and pharmacy board layers that govern the specific words a clinic may use in patient-facing communication.
Primary Care · North Dallas, TXCase study →
MedSpa · North Dallas, TX
Skin Care · Beverly Hills, CA
Dental · Christiansburg, VACase study →
Pediatrics · Blacksburg, VACase study →
Pediatric Dentistry · Blacksburg, VACase study →
Dental · Roanoke, VACase study →
Functional Medicine · Telehealth · USACase study →
“When I first approached Ichelon Consulting, my YouTube channel was stuck and despite my own efforts, it was not growing. They created a specific strategy which was based on SEO, and completely evaluating the channel, which worked great and has propelled our YouTube channel to new heights. Because of the channel growth, we have seen new patient consultations coming on a regular basis.”
GLP-1 receptor agonists are the fastest-growing category in weight-management pharmacotherapy. Understanding what is FDA-approved for what indication is the foundation of every compliance decision in the vertical.
Advertising a diabetes brand for weight loss is off-label promotion. Advertising Wegovy or Zepbound for weight loss is on-label. This distinction structures every downstream compliance decision — copy that names a diabetes brand alongside weight-loss claims, or copy that presents diabetes brands interchangeably with weight-loss brands, sits in off-label promotion territory and must be treated as such.
Compounding is the preparation of a drug for an individual patient by combining, mixing or altering ingredients. Federal law recognises two compounding pathways.
Section 503A of the FD&C Act permits state-licensed pharmacies and physicians to compound drugs for individually identified patients pursuant to a valid prescription. The compounder must operate in compliance with state pharmacy law, use bulk substances that appear on FDA's list of substances that may be used, and meet specific labelling and record-keeping requirements. A 503A compounder is not registered with the FDA.
Section 503B, added by the Drug Quality and Security Act of 2013, permits outsourcing facilities to compound drugs in bulk without patient-specific prescriptions. 503B facilities register with the FDA, must comply with current good manufacturing practice (cGMP), and are inspected by the FDA on a schedule. 503B facilities can supply compounded medications to clinics on a wholesale basis.
Both 503A and 503B permit the compounding of drugs that are on FDA's official drug-shortage list, subject to certain conditions. Semaglutide and tirzepatide have appeared on and been removed from the shortage list at various points during the GLP-1 supply cycle. When a drug comes off the shortage list, the federal justification for compounding narrows and enforcement risk increases correspondingly.
State pharmacy law adds a second layer on top of federal 503A and 503B. Some states are broadly permissive of physician-prescribed compounded medications delivered through licensed compounding pharmacies; others are narrower. The picture is regularly changing and any practice advertising compounded GLP-1s in multiple states needs current state-by-state confirmation before publishing marketing that presumes availability.
These lists reflect general regulatory posture and are not a substitute for current legal advice. Regulatory bulletins, state pharmacy board notices and federal shortage-list changes can move a state from one column to another within weeks. The operational rule is that no compounded-GLP-1 campaign should be scaled to multiple states without a written, current legal check on each target state.
Ozempic and Mounjaro are FDA-approved for type 2 diabetes. Prescribing them for weight loss is off-label. Physicians may lawfully do so in the practice of medicine. What is restricted is promotion of the diabetes brand for the off-label weight-loss use, as covered in detail in our companion off-label injectable FDA guide.
The practical rule for weight-loss clinic marketing is:
Meta's advertising standards treat weight-loss and body-image content as a sensitive category. The two provisions that most affect US weight-loss clinic marketing are:
Additional Meta restrictions relevant to weight-loss clinics include the prohibition on targeting minors, on before-and-after imagery in the ad creative (though on the practice's own website, subject to appropriate consent and disclaimers), and on ads that make specific unqualified outcome claims.
TikTok's Community Guidelines and separate Advertising Policies restrict content that promotes or provides instructions on obtaining prescription drugs outside a physician-directed context. Prescription medication ads are broadly restricted; healthcare service ads are permitted with additional review.
The nuance for weight-loss clinics is that verified physician creators have significant latitude for educational content — explaining GLP-1 mechanism, discussing patient selection criteria, sharing clinical decision-making in a professional voice, engaging with viewer questions. That content is not treated as an advertisement.
The line is crossed when:
Physician creators partnering with a weight-loss clinic should sign an agreement that mirrors the FTC 16 CFR 255 material-connection disclosure standard and adds TikTok-specific commitments — no direct product promotion, no unqualified outcome claims, education-first framing, clinical-context disclosure on any patient-specific content.
Wegovy, Zepbound, Saxenda for on-label weight-loss copy. Ozempic and Mounjaro referenced only in physician-first-person off-label context on the clinic's own site. Compounded options disclosed with state permissibility and compounded-versus-branded distinction.
Current written confirmation from counsel for every target state before scaling advertising that presumes availability of a compounded option. Refresh quarterly at minimum.
Copy calibrated to service description, not personal-condition addressing. Category-level and aspirational, never "are you overweight." Landing pages consistent with the ad.
Written agreement with every physician or influencer creator: material-connection disclosure standard, education-first framing, no unqualified outcome claims, no direct product promotion, clinical-context disclosure on patient-specific content.
Ad copy that names Wegovy, Zepbound, Saxenda calibrated for restricted-medicines review. Compounded-product ads acknowledged as heavily restricted; alternative campaign structures for compounded offerings.
Every state medical board has advertising rules that reach weight-loss clinics. The elements that concentrate risk are:
The compounded-medications overlay adds state pharmacy board involvement. Compounded-medication advertising that overstates equivalence to branded products, misrepresents the compounding pathway, or omits the state permissibility caveat is exposed to state pharmacy board enforcement in addition to medical board enforcement.
Every GLP-1 marketing engagement is reviewed by a senior member of the Leadership Team with visibility into FDA compounding enforcement patterns, Meta and TikTok health-policy escalations, and the state medical and pharmacy board layers.
ICG's results are reproducible because they are built on proprietary infrastructure — not agency intuition or generic tools. These nine HealthApex OS platforms are what power every ICG engagement.
WhatsApp AI Lead Qualifier
An AI assistant that holds a short WhatsApp conversation with every enquiry, decides whether it fits your criteria, and posts qualified leads to your CRM labelled Qualified. Team inbox, campaigns and consent handling included. $40/mo for US practices.
CRM Intelligence & Lead-Ops MIS
Sits as the business intelligence layer above your CRM — AtomCRM or any other CRM you run, including custom builds. Shows where leads are leaking, which effort is wasted, and which good leads were quietly downgraded by automation — not by a human decision.
Attribution Engine & CAPI Middleware
Sits at the centre of every ICG attribution architecture. CAPI middleware connecting Meta Ads, Google Ads, WhatsApp and IVR to your CRM. Lifts Event Match Quality from 2.5 to 6+, reducing CPM 30–40% from the same budget.
PMS with built-in revenue intelligence layer
A PMS built to track cross-sell and up-sell opportunities within your existing patient base. 12 modules covering OPD, IPD, Pharmacy, Labs, Billing, Inventory, Patient Portal, Smart Scheduling, RBAC, AES-256 encrypted storage.
Revenue intelligence built over your existing PMS
If you already have a PMS, whichever one it is, Phoenix builds the business intelligence layer on top of it without replacement. Built for single clinics and multi-centre chains alike.
YouTube analytics that measures patients, not views
A YouTube intelligence platform built for healthcare business outcomes. Connects video performance to actual consultation bookings — not views, not subscribers. Patient testimonial videos generate 6.9× more consultations per view than condition explainers.
Full transparency. Instant diagnosis. Zero surprises.
ICG's centralised governance platform — every client sees everything in real time, and ICG's team sees every problem the moment it surfaces. 30+ real-time alert systems fire the moment a metric drifts outside its performance envelope.
AI Overview + LLM citation tracking, healthcare-tuned
Knows the moment ChatGPT, Perplexity, Google AI Overviews and Gemini cite your brand in patient answers — and which content drove the citation. Bot-aware dashboard with GA4-registered custom dims (AIO source, AIO referrer) and IndexNow + GSC API integration.
Every Meta + Google ad your competitors run, watched daily
Tracks 75+ Indian healthcare brands, 2,150+ active ads, ₹50Cr+ aggregate ad spend visibility per month. Surfaces what's working, what's been killed, what offers are emerging. Powers every ICG Meta Ads brief, Performance Marketing diagnostic, and IVF / derm / dental specialty campaign with real competitive intelligence.
Every Google Business Profile scored, tracked, protected, and grown from one command centre
ICG's proprietary Google Business Profile intelligence platform. Scores every listing across 7 dimensions, tracks rank on a live geo-grid across your actual service area, audits NAP + citations, monitors 531 suspension-risk factors continuously, and drafts Google Posts on cadence. Currently managing 143 healthcare listings with 0 suspensions and 4.76★ portfolio average across 28,137 reviews.
Every ICG engagement runs on some combination of these ten HealthApex OS tools. The diagnostic determines which combination is right for your practice.
Explore HealthApex OS → See the full stack live on your account — free 30-min audit →Federal law permits 503A/503B compounding under specific conditions. State pharmacy law varies. Florida, Arizona and Texas have historically been permissive; California and New York apply narrower rules. Confirm with counsel before advertising.
503A permits traditional patient-specific compounding by state-licensed pharmacies. 503B permits outsourcing facilities to compound in bulk under FDA registration and cGMP. Both are the vehicles for compounded GLP-1s.
Wegovy is approved for chronic weight management. Ozempic is approved for type 2 diabetes, not weight loss — prescribing it for weight loss is off-label.
Zepbound is approved for chronic weight management. Mounjaro is approved for type 2 diabetes, not weight loss — prescribing it for weight loss is off-label.
US weight-loss ads are heavily restricted but not banned. Aspiration and service-description framing pass; personal-attribute-addressed copy fails. No targeting of minors. Landing pages consistent with the ad.
Verified physician creators can produce educational content on mechanism, patient selection and clinical experience. Ads and creator content promoting specific compounded products face heavy restriction.
Yes for licensed medical weight-loss services under the Healthcare and Medicines policy. Naming specific prescription products triggers restricted-medicines review; compounded-brand ads are generally not permitted in ordinary channels.
Every state has rules on truthful presentation of results, disclosure of the physician of record and prohibitions on unsupported claims. California, Florida, Texas and New York are among the most active. State pharmacy boards also regulate the compounding side.
Telemedicine adds interstate practice rules and telehealth-specific advertising requirements. Some states have specific telehealth prescribing and dispensing rules; a clinic operating across state lines needs a per-state compliance review before advertising nationally.
Yes, when the clinic offers non-pharmacologic programmes (nutrition coaching, behaviour change, exercise physiology). The advertising remains subject to FTC substantiation, state medical board rules and Meta Personal Attributes, but the GLP-1 and compounding layers do not apply.
Book a 30-minute call with a senior member of the Leadership Team, email the US practice lead, or call the Dallas office. Retainers are custom-scoped per engagement · from USD 250 per month equivalent, with GLP-1 marketing audits priced on scope.
A representative slice of the 150+ healthcare brands ICG has delivered for across India. Full client list available under NDA during a Brand and Growth Diagnostic.
Our US team will reach out within one business day. For a faster reply, WhatsApp us or call +1 (724) 612-3694.
💬 WhatsApp Us
Director, Ichelon Consulting US. Book a free 30-minute diagnostic and we'll show you what we'd fix first for your practice.
Book a free diagnostic → WhatsApp Us
